Ga-68 PSMA-11 / -617 PET imaging — selection, biochemical-recurrence detection, intra-prostatic mapping. Curated daily from Europe PMC (PubMed + PMC + preprints) and OpenAlex — free-full-text link on each open-access paper.
Jialiang Deng, Guoxiong Ma, Weijin Chen, Songhao Wen et al.
[ 177 Lu]Lu-PSMA radioligand therapy (LuPSMA RLT) has improved outcomes for patients with metastatic castration-resistant prostate cancer (mCRPC), yet clinically meaningful response heterogeneity persists even among patients selected on the basis of PSMA PET positivity. A central limitation of patient-level PSMA eligibility is that it establishes target availability in at least…
Solitary corpus cavernosum metastasis from prostate cancer is extremely rare, particularly as an isolated nodular lesion. We report 2 patients who developed rapid prostate-specific antigen (PSA) elevation following radical prostatectomy without prior evidence of metastatic disease. 68Ga-PSMA PET revealed isolated PSMA-avid nodules in the corpus cavernosum (SUVmax: 4.46 and 22.4…
Omar Alghazo, Thomas Milton, Kate Wilson, Mrunal Hiwase et al.
Abstract Objective To evaluate the diagnostic efficacy of prostate-specific membrane antigen positron emission tomography–computed tomography (PSMA PET–CT) in detecting and localising recurrence in patients with biochemical relapse (BCR) following definitive radiotherapy for prostate cancer. Methods A systematic review and meta-analysis was conducted according to PRISMA guideli…
Matthew Benger, Georgios Krokos, Karan Daga, Alan J. Wright et al.
Abstract Prostate-specific membrane antigen (PSMA) is upregulated in high-grade glioma (HGG). This study aimed, firstly, to establish dosimetry for the radionuclide [68Ga]-PSMA-11 in HGG patients; secondly, to determine theoretical tumour doses for [177Lu]-PSMA, a potential therapeutic radionuclide; thirdly, to assess PSMA immunohistochemistry in targeted intra-operative HGG bi…
The application of artificial intelligence (AI) in positron emission tomography (PET)-based internal dosimetry in radiopharmaceutical therapy (RPT), with an emphasis on the paradigm shift from resource-consuming multi-time-point acquisition protocols toward efficient data-driven dosimetric frameworks. Machine learning (ML) models capable of determining organ- and patient-specif…
Hongyi Wang, Yan Yan, Yueping Li, Sihan Chen et al.
Despite the remarkable therapeutic efficacy of chimeric antigen receptor T (CAR-T) cell therapy in hematologic malignancies, its clinical translation in solid tumors remains impeded by challenges including insufficient intratumoral infiltration, tumor heterogeneity, and the immunosuppressive tumor microenvironment. Molecular imaging, which enables the visualization and quantita…
Mahbod Jafarvand, Andrea Farolfi, Riccardo Mei, Loïc Djaileb et al.
Prostate-specific membrane antigen (PSMA)–targeted PET/CT (PSMA PET/CT) has become the first-line imaging modality used for staging and restaging prostate cancer. Its utility after minimally invasive focal therapy (high-intensity focused ultrasound, laser ablation, cryoablation) remains unclear. This study evaluated PSMA PET/CT for detecting and localizing recurrence after foca…
Saruta M, Shiroki R, Takeuchi A, Yoshizawa A et al.
Abstract Objectives This study evaluated the feasibility and safety of 68 Ga-PSMA-11 PET/CT using an in-house cyclotron-produced 68 Ga in patients with prostate cancer. Methods We prospectively included 10 patients across clinically relevant disease settings: biochemical recurrence after definitive local therapy, non-metastatic castration-resistant prostate cancer, and metastat…
Luca Russo, Ossian Longoria, Silvia Bottazzi, Nuria Porta et al.
Background Unequivocal clinical progression without radiological progression according to Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria is recognised in metastatic castration-resistant prostate cancer (mCRPC), reflecting limitations of bone scintigraphy in distinguishing an osteoblastic progression from an osteoblastic flare. Objective To compare the METastas…
Leonardo Lampertico, Gaia Muti, C. Carbonini, Chiara Romanò et al.
The accuracy of quantitative lutetium-177 single-photon emission computed tomography/computed tomography (¹⁷⁷Lu SPECT/CT) depends on the imaging system, acquisition protocol, reconstruction algorithm, and calibration strategy. This study aimed to develop and evaluate a practical commissioning workflow to optimize ¹⁷⁷Lu imaging across different commercial scanner–reconstruction …
E Novruzov, Eduards Mamlins, Joseph Kabunda, Jens Cardinale et al.
Abstract Background PSMA-PET/CT became an important means for prostate cancer management. The high-resolution and signal-to-noise ratio of PET is mandatory in primary staging or biochemical relapse that often present with tiny lesions. PSMA-PET is also used to select patients for PSMA-targeted radioligand-therapy, but scanner availability increasingly becomes a bottleneck. The …
Luca Urso, Stefano Panareo, Domenico Albano, Antonella Iudicello et al.
Abstract Purpose Triple negative breast cancer (TNBC) is an aggressive subtype, still with limited therapeutic options. [ 18 F]FDG PET/CT is widely used in TNBC, but evidence regarding its prognostic value remains limited. The TRINE PET study, promoted by the Italian Association of Nuclear Medicine, aimed to evaluate the prognostic relevance and clinical impact of [ 18 F]FDG PE…
To explore how core backbone modifications influence prostate-specific membrane antigen (PSMA) targeting, we synthesized a series of novel peptidomimetics replacing the classic urea linkage of established radiotracers with a carbamate functionality. This panel systematically varied side chain length (aspartic vs. aminoadipic acid), stereocenter configuration (S/S vs. S/R diaste…
Adrien Holzgreve, Sophie C. Siegmund, Liam Widjaja, Rudolf A. Werner
management of patients with advanced prostate cancer, firmly anchored in clinical guidelines [8].This article provides an update on established PSMA theranostics using beta-emitting ligands, based on major clinical trial results.It then continues with an overview of more recent developments in the field of PSMA radiotheranostics, focusing on alpha-based approaches, in particula…
Bekkhoucha A, Zaragori T, Olivier P, Claudin M et al.
Prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy with [177Lu]Lu-PSMA-617 has reshaped the management of metastatic castration-resistant prostate cancer (mCRPC). This study aimed to assess the added prognostic value of [18F]FDG PET beyond [68Ga]Ga-PSMA-11 PET as pretreatment imaging and to develop an overall survival (OS) nomogram for patients with …
[177Lu]Lu-PSMA-617 is an approved therapy for metastatic castration-resistant prostate cancer (mCRPC); however, response rates vary significantly, particularly among patients with low prostate-specific membrane antigen (PSMA) expression on PSMA PET. This multicenter, open-label phase 2 trial evaluates the efficacy and safety of an intensified Lu-PSMA treatment schedule in patie…
Abstract Objectives To investigate the associations of ¹⁸F-FDG PET/CT and ⁶⁸Ga-PSMA-11 PET/CT parameters with salivary gland ultrasonography abnormalities and unstimulated whole salivary flow rate in patients with Sjögren’s disease. Methods Twenty-three patients with SjD who had undergone ¹⁸F-FDG PET/CT within the previous 6 months subsequently underwent ⁶⁸Ga-PSMA-11 PET/CT. FD…
Diagnostic Reference Levels (DRLs) are benchmarks for optimizing radiation doses in medical imaging. This study establishes new national DRLs (NDRLs) for PET/CT examinations in Switzerland based on a multicentre survey. Administered activities for PET examinations and dose indicators for localization / attenuation correction (AC) CT scans were collected in Swiss nuclear medicin…
A contemporary standard of care for patients with metastatic androgen pathway modulator-naive/sensitive (APMN/S) prostate cancer (also known as metastatic hormone-sensitive prostate cancer) is androgen deprivation therapy (ADT) plus an androgen receptor pathway inhibitor (ARPI) until progression. PSMAddition aimed to evaluate the efficacy and safety of [177Lu]Lu-PSMA-617 (177Lu…
Al Said AT, Rahman AA, Albadarneh LK, Oglat AA et al.
BackgroundPositron Emission Tomography/Computed Tomography (PET/CT) is a crucial imaging modality widely used for diagnosing and staging various cancers. Although patient weight is known to influence radiation dose, there is limited research on optimizing PET/CT protocols based on weight categories to minimize unnecessary exposure.ObjectivesThis study evaluates the effective do…
Gallium-68-prostate-specific membrane antigen (68Ga-PSMA-11) positron emission tomography/computed tomography (PET/CT) is a key imaging modality for evaluating prostate cancer. Here we report two cases of unexpected positive 68Ga-PSMA-11 uptake in stroke lesions during prostate cancer assessment. The first patient suffered from cerebral hemorrhage in the right frontal lobe, and…
Mangale P, Agrawal A, Choudhury S, Prakash G et al.
AimAssessment of maximum standardized uptake value (SUVmax) values and patterns of uptake on 68Ga prostate-specific membrane antigen (PSMA) PET/computed tomography (CT) in benign and malignant prostatic lesions.MethodsRetrospective observational study of prostate cancer patients referred for 68Ga-PSMA PET/CT for initial staging. SUVmax of the prostatic lesion was correlated wit…
Nuthalapati M, Patravale T, Solomon N, Menon AR et al.
Biochemical recurrence (BCR) after radical prostatectomy occurs in 20-40% of patients. Prostate-specific membrane antigen (PSMA) PET/computed tomography (CT) is the preferred imaging modality for recurrence, but detection rates decline at low prostate-specific antigen (PSA) levels. The role of PSA kinetics in postradical prostatectomy BCR remains unclear. We evaluated the assoc…
The detection of biochemical recurrence (BCR) of prostate cancer remains challenging, as small-volume disease may fall below the sensitivity of standard imaging. Prostate-specific membrane antigen (PSMA) PET/CT is currently the most sensitive imaging modality for tumor detection at low prostate-specific antigen (PSA) levels, but recurrence continues to be difficult to detect. W…
Mehdikhani B, Damavand RS, Zolfi E, Narimani N et al.
Abstract Background. Accurate pelvic lymph node (N1) staging governs treatment selection in intermediate-to-high-risk prostate cancer, yet conventional imaging is insensitive to small nodal deposits. Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) is increasingly used for primary staging, but its per-patient accuracy against a h…
Rauscher I, Langbein T, Elshenawy K, Hein S et al.
Abstract Purpose To qualitatively and quantitatively compare 18 F-flotufolastat-PET and 68 Ga-PSMA-11-PET urinary and lesion activity in a matched cohort of primary prostate cancer patients. Methods Data from patients who underwent 18 F-flotufolastat-PET or 68 Ga-PSMA‑11-PET (n=62 each) were cohort-matched by disease characteristics. An experienced nuclear medicine physician as…
ObjectiveThis Phase I/IIa study evaluated the safety, pharmacokinetics, internal radiation dosimetry, and image quality of cyclotron-produced ⁶⁸Ga-PSMA-11 synthesized using an automated module in a Japanese population.MethodsIn this single-center trial, nine Japanese men (3 healthy volunteers, 6 prostate cancer patients) received a single intravenous injection of ⁶⁸Ga-PSMA-11 (…
Magnetic resonance imaging (MRI) and prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) are increasingly used together in patients with suspected or confirmed prostate cancer (PCa). Discordant findings are common because these modalities evaluate different biological and anatomical aspects of the disease. MRI is best suited for int…
BackgroundTo evaluate whether 99mTc-MIP-1404 CZT SPECT/CT is non-inferior to 68Ga-PSMA-11 PET/CT for metastases detection in patients with newly diagnosed high risk prostate cancer (PCa). Patients with newly diagnosed high-risk PCa (age range 50-79 years, mean 66) underwent three imaging modalities: 99mTc-HDP CZT SPECT/CT, 68Ga-PSMA-11 PET/CE-CT (contrast-enhanced CT), and 99mT…
PurposeTo evaluate lesion detection patterns and the risk-stratification value of paired 68Ga-PSMA-11 and 18F-FDG PET/CT in patients with post-prostatectomy biochemical recurrence (BCR) and negative conventional imaging, and to explore the hypothesis-generating biological context of dual-tracer phenotypes using public single-cell transcriptomic data.MethodsThis retrospective si…
To improve the theranostic efficacy of PSMA-targeted radiopharmaceuticals on patients with medium-to-low PSMA expression, we radiolabeled a series of novel designed PSMA-targeting dimer agents to improve tumor imaging and treatment outcomes under challenging conditions. All agents were successfully radiolabeled with 68Ga in moderate decay-corrected labeling yield and high radio…
This study aimed to validate an automated lesion-tracking algorithm for [68Ga]Ga-PSMA-11 PET/CT against expert reference matches and to evaluate its integration into three PSMA-specific treatment response frameworks-the Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0), PSMA PET Progression (PPP) criteria, and the Traffic Light Workflow (TLW)-in men with biochemically rec…
We investigated the prognostic value of baseline [18F]FDG and [68Ga]Ga-PSMA-11 PET/CT in patients with metastatic castration-resistant prostate cancer treated with [177Lu]Lu-PSMA-617. Methods: In this multicenter retrospective study, the associations between several clinical, biologic, and radiologic parameters and overall survival (OS) were tested in a development cohort using…
Schmidt CJ, Gaertner FC, Kreppel B, Essler M et al.
This study aimed to externally validate the P-Score, a composite scoring system combining PI-RADS and PRIMARY score, for its diagnostic accuracy in detecting clinically significant (ISUP ≥ 2) and higher-grade (ISUP ≥ 3) prostate cancer (PCa). 230 biopsy-naïve men with suspected PCa were prospectively enrolled in the DEPROMP trial and underwent multiparametric MRI and [68Ga]Ga-D…
Prostate-specific membrane antigen (PSMA)-based theragnostics has transformed precision oncology by integrating molecular imaging and targeted radionuclide therapy in prostate cancer (PCa). This review outlines the mechanistic rationale of PSMA targeting, radiopharmaceutical design, and diagnostic applications of 68Ga-PSMA-11 positron emission tomography (PET)/computed tomograp…
Jeblick K, Schachtner B, Mittermeier A, Dexl J et al.
We describe a publicly available, large, annotated dataset of 597 whole-body Positron Emission Tomography/Computed Tomography (PET/CT) studies with Prostate-Specific Membrane Antigen (PSMA)-targeting radiotracers ([18 F]PSMA and [68Ga]Ga-PSMA-11) from 378 male patients with suspected or diagnosed prostate carcinoma. Scans were acquired between 2014 and 2022 on three clinical PE…
ObjectivesThis study evaluated the prognostic value of intraprostatic maximum standardized uptake value (SUV max ) on primary-staging gallium-68 prostate-specific membrane antigen ( 68 Ga-PSMA) PET/computed tomography for predicting biochemical recurrence (BCR) and BCR-free survival after margin-negative radical prostatectomy, and explored an SUV max cutoff.MethodsThis retrospe…
ObjectiveTo evaluate whether adding PSMA PET-detected lymph node involvement to established nomograms (Briganti-2019 and MSKCC) improves prediction of pathologic lymph node metastasis(LNM) in prostate cancer.Materials and methodsRetrospective, registry-based, multi-center cohort coordinated by the Turkish Urooncology Association, with data from 10 centers. We included 301 men u…
A 68-year-old man with gastric cancer underwent 18F-fluorodeoxyglucose (FDG) PET/CT, which revealed an incidental subcutaneous lesion suspicious for low-grade sarcoma or metastasis. The patient initially declined a biopsy. One month later, following a new diagnosis of prostate cancer, 68Ga-prostate-specific membrane antigen (PSMA) PET/CT was performed. The unchanged lesion demo…
Ulaner GA, Parihar AS, Calais J, Sutcliffe S et al.
Purpose To perform a systematic review and meta-analysis of liver background uptake across four prostate-specific membrane antigen (PSMA)-targeting PET radiotracers (fluorine 18 [18F]-piflufolastat, gallium 68 [68Ga]-PSMA-11, 18F-flotufolastat, and 18F-PSMA-1007) and evaluate the potential impact on patient selection for PSMA-targeted therapy. Materials and Methods A comprehens…
BackgroundGallium-68 (68Ga) is a PET isotope that is finding more use in the clinical setting as a PET diagnostic tool, for example 68Ga PSMA is widely used in the diagnosis of prostate cancer, and 68Ga dotatate for the diagnosis of neuroendocrine tumors. Current production is mostly performed using either 68Ge/68Ga generators or liquid targets containing 68Zn and irradiated wi…
BackgroundWe aimed to explore the value of prostate-specific membrane antigen (PSMA) and 18F-FDG PET/CT in efficacy evaluation and prognosis analysis for patients with metastatic castration-resistant prostate cancer (mCRPC) who underwent Lutetium-177-labeled Evans blue-modified PSMA (177Lu-EB-PSMA) therapy.MethodsThis study retrospectively enrolled 35 mCRPC patients who receive…
Tell us who you are and we’ll send the full product brochure to your institutional email after a quick review. We respond within one working day (Mon–Fri, 9:30–18:30 IST).
Request received
A Saxsons sales engineer will review your request and send the brochure to your institutional email within one working day. You may receive a verification call before processing.
